.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX19_DasiprotimutT.DasiprotimutT .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX19_DasiprotimutT.DasiprotimutT| name: | DasiprotimutT |
| ATC code: | L03AX19 | route: | subcutaneous |
| n-compartments | 1 |
Dasiprotimut-T is a therapeutic cancer vaccine consisting of a pool of seven synthetic peptides derived from tumor-associated antigens (TAAs) conjugated to keyhole limpet hemocyanin and mixed with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an adjuvant. It has been primarily investigated for use in melanoma as an immunotherapeutic agent. It is not approved for general clinical use at this time and remains in clinical trial investigations.
No published pharmacokinetic (PK) parameters have been reported in the literature for dasiprotimut-T in any specific population or setting, as is typical for vaccine-based immunotherapies composed of peptides and adjuvants.